Transgene Biotek quarterly results and financials

Transgene Biotek (BSE 526139)₹2.52+1.20%(9 Nov 2026 close)Healthcare Service Provider

Key facts

In the Jun 2026 quarter (consolidated), Transgene Biotek reported sales of ₹0.05 Cr, up 25.0% from Jun 2025, and net profit of −₹0.40 Cr. For the year to Mar 2026, sales were ₹0.20 Cr and net profit −₹1.66 Cr.

Sales (Jun 2026): ₹0.05 Cr
Net profit (Jun 2026): −₹0.40 Cr
Sales (FY Mar 2026): ₹0.20 Cr
Net profit (FY Mar 2026): −₹1.66 Cr
EPS (Jun 2026): ₹−0.06
Borrowings (Mar 2026): ₹17.19 Cr

Company filings, consolidated accounts; latest reported quarter Jun 2026

Transgene Biotek quarterly results

₹ crore unless stated; each column is a quarter.

Transgene Biotek Quarterly results
	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	0.04	0.04	0.04	0.04	0.05	0.07	0.07	0.04	0.04	0.04	0.04	0.05
Expenses	0.16	0.15	0.31	0.45	0.12	0.16	0.61	0.19	0.12	0.09	0.32	0.11
Operating Profit	−0.13	−0.12	−0.28	−0.42	−0.08	−0.10	−0.55	−0.14	−0.09	−0.06	−0.29	−0.07
OPM %	−240.0%	−220.0%	−540.1%	−820.0%	−116.7%	−112.5%	−675.0%	−260.0%	−160.0%	−100.0%	−560.0%	−100.0%
Other Income	0.05	0.05	0.06	0.66	0.05	0.05	0.05	0.00	0.00	0.00	0.16	0.00
Interest	0.02	0.02	0.02	0.03	0.03	0.01	0.20	0.24	0.25	0.26	0.29	0.28
Depreciation	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.06	0.06	0.06	0.06	0.05
Profit before tax	−0.14	−0.13	−0.28	0.21	−0.08	−0.10	−0.72	−0.44	−0.40	−0.38	−0.47	−0.40
Tax %	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net Profit	−0.14	−0.13	−0.28	0.21	−0.08	−0.10	−0.72	−0.44	−0.40	−0.38	−0.47	−0.40
EPS (Rs)	−0.03	−0.03	−0.05	0.04	−0.02	−0.02	−0.10	−0.07	−0.06	−0.06	−0.07	−0.06

Transgene Biotek profit and loss

₹ crore unless stated; years end in March. TTM is the last four quarters.

Transgene Biotek Profit and loss
	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	0.17	0.27	0.11	0.06	0.00	0.16	0.08	0.05	0.22	0.25	0.20	0.17
Expenses	1.31	2.83	2.21	0.74	0.86	0.69	0.54	0.67	0.82	1.37	0.74	0.64
Operating Profit	−1.15	−2.57	−2.11	−0.69	−0.88	−0.54	−0.47	−0.63	−0.61	−1.13	−0.55	−0.51
OPM %	−633.3%	−914.3%	−1,750.0%	−971.5%	—	−311.8%	−511.1%	−1,033.3%	−260.9%	−430.8%	−257.2%	−300.0%
Other Income	0.18	0.67	7.38	2.05	0.19	0.28	0.22	0.19	0.19	0.79	0.16	0.16
Interest	0.06	0.42	1.04	0.25	0.37	0.26	0.22	0.63	0.13	0.25	1.07	1.08
Depreciation	20.55	17.57	9.92	9.92	9.92	9.94	9.94	4.96	0.10	0.10	0.21	0.23
Profit before tax	−21.62	−19.95	−5.67	−8.82	−11.02	−10.48	−10.44	−6.03	−0.66	−0.68	−1.66	−1.65
Tax %	0.0%	0.0%	14.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	—
Exceptional items	0.00	0.00	2.99	1.99	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—
Net Profit	−21.64	−19.93	−6.47	−8.83	−11.01	−10.47	−10.44	−6.03	−0.67	−0.69	−1.66	−1.65
EPS (Rs)	−2.85	−2.63	−0.86	−1.17	−1.46	−1.39	−1.38	−0.80	−0.10	−0.10	−0.23	−0.25
Dividend payout %	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	—

Transgene Biotek balance sheet

₹ crore, at each year end.

Transgene Biotek Balance sheet
	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	76.08	76.09	75.99	76.05	76.09	76.06	76.01	75.99	76.03	76.06	76.00	76.07
Reserves	116	98.91	−16.92	−23.36	−32.19	−43.16	−53.59	−58.46	−64.48	−65.09	−65.84	−67.41
Borrowings	14.48	15.32	16.05	9.87	9.16	10.36	11.36	12.04	13.15	14.03	14.56	17.19
Other Liabilities	139	124	124	125	124	124	124	118	118	118	120	118
Total Liabilities	345	314	199	187	177	167	158	148	143	143	145	144
Fixed Assets	164	141	61.40	51.15	41.26	31.33	21.39	11.44	6.47	6.38	7.99	9.67
CWIP	0.28	0.28	2.03	1.86	1.86	1.86	1.86	1.86	1.86	1.86	1.86	0.00
Investments	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.11	0.11	0.11	0.11	0.10
Other Assets	181	172	135	134	134	134	134	134	135	135	135	134
Inventories	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Trade receivables	16.07	2.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash & equivalents	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Assets	345	314	199	187	177	167	158	148	143	143	145	144

Transgene Biotek cash flow

₹ crore, for each year.

Transgene Biotek Cash flow
	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2025	Mar 2026
Cash from operating activity	3.51	6.46	0.03	−0.62	−1.73	0.13	0.00	0.09	0.00	1.19	−0.02
Cash from investing activity	−4.56	−6.46	0.00	3.04	1.73	0.00	−0.02	−0.09	0.00	−1.69	0.14
Cash from financing activity	1.02	0.00	0.00	−2.36	0.00	−0.19	0.00	0.00	0.00	0.77	−0.35
Net cash flow	−0.01	0.00	0.01	0.04	0.00	−0.05	0.00	0.00	0.00	0.27	−0.21
Capex	4.58	6.48	0.00	0.00	0.09	0.00	0.02	0.00	0.00	1.69	0.00
Free cash flow	−1.06	0.00	0.03	2.75	−0.02	0.15	−0.03	0.11	0.00	−0.51	0.15
CFO / OP %	−220.0%	−568.0%	−1.0%	30.0%	256.0%	−16.0%	−2.0%	−22.0%	0.0%	−107.0%	2.0%

Transgene Biotek ratios

Working-capital days and returns, by year.

Transgene Biotek Ratios
	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor days	19,953	3,326	13	30	52	—	21	41	61	16	14	17
Inventory days	—	—	—	364	364	1,459	121	—	155	—	—	—
Days payable	—	—	—	5,020	3,529	13,871	1,461	—	1,200	—	—	—
Cash conversion cycle	19,952	3,325	12	−4,624	−3,112	—	−1,318	40	−983	15	13	16
Working capital days	−8,530	−16,020	−14,340	−39,968	−62,520	—	−29,094	−34,595	−57,367	−15,934	−16,510	−21,362
ROCE %	−8.8%	−10.8%	−14.6%	−10.9%	−17.9%	−22.1%	−26.5%	−32.3%	−19.9%	−2.1%	−1.7%	−2.4%

Transgene Biotek: frequently asked questions

What are the latest quarterly results of Transgene Biotek?

For the Jun 2026 quarter, Transgene Biotek reported sales of ₹0.05 Cr, up 25.0% year on year and net profit of −₹0.40 Cr. The operating margin was −100.0%.

What is the annual revenue of Transgene Biotek?

Transgene Biotek's sales for the year to Mar 2026 were ₹0.20 Cr; over the last twelve months they were ₹0.17 Cr.

What is the net profit of Transgene Biotek?

Net profit for the year to Mar 2026 was −₹1.66 Cr, and −₹1.65 Cr over the last twelve months. Earnings per share over the same trailing period were ₹−0.25.

How much debt does Transgene Biotek have?

Transgene Biotek reported borrowings of ₹17.19 Cr at Mar 2026, against cash and equivalents of ₹0 Cr.

What is the free cash flow of Transgene Biotek?

Cash from operations was −₹0.02 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹0.15 Cr.

Loading…